BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Issues New Health Warning For RU-486


10/19/2005 5:11:40 PM

The U.S. Food and Drug Administration issued a public health advisory Tuesday night for the abortion pill mifepristone, better known as RU-486. The agency said in a press release that it is investigating four new reports of death, all in California, following use of RU-486 for medical abortions. All the deaths occurred between September 2003 and June 2005. The advisory follows previous reports of serious bacterial infection, bleeding, ectopic pregnancies that have ruptured, and death; the drug's black box label warning was subsequently strengthened in 2004. The latest advisory warns of the risk of sepsis or blood infection when having a medical abortion using RU-486. Two of the four deaths involved infection with Clostridium sordelli, a bacteria that can produce fatal toxins in rare cases following childbirth or medical abortions. The FDA action follows an announcement Monday by Danco Laboratories, which markets the drug as Mifeprex, that it was modifying the label to update the safety information.

Read at AP
Read at HealthDay
Read at WebMD

AP
HealthDay
WebMD
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES